Provided by Tiger Fintech (Singapore) Pte. Ltd.

United Therapeutics

302.41
-2.4000-0.79%
Post-market: 302.410.00000.00%17:49 EDT
Volume:540.91K
Turnover:163.71M
Market Cap:13.68B
PE:11.80
High:307.06
Open:301.85
Low:299.45
Close:304.81
Loading ...

UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating

MT Newswires Live
·
30 Jun

Paul A. Mahon, EVP & General Counsel, Reports Disposal of United Therapeutics Corp Common Shares

Reuters
·
28 Jun

United Therapeutics Shareholders Approve Key Resolutions

TIPRANKS
·
27 Jun

United Therapeutics Corporation Conducted Annual Shareholders Meeting

Reuters
·
27 Jun

United Therapeutics Directors Make Significant Stock Moves!

TIPRANKS
·
26 Jun

Director Nilda Mesa Reports Disposal of Common Shares in United Therapeutics Corporation

Reuters
·
26 Jun

Director Richard Giltner Reports Disposal of United Therapeutics Corporation Common Shares

Reuters
·
26 Jun

United Therapeutics’ Ralinepag Study: A Potential Game-Changer for PAH Treatment

TIPRANKS
·
25 Jun

United Therapeutics and Intermountain Health Partner for Groundbreaking Bioengineered Liver Trial

Reuters
·
24 Jun

Liquidia Corporation Expands Manufacturing Capabilities Amid Successful YUTREPIA Launch and Secures Additional $50 Million Funding from HCRx

Reuters
·
24 Jun

BRIEF-United Therapeutics Corporation Concludes Enrollment Of The Advance Outcomes Study Of Ralinepag

Reuters
·
23 Jun

United Therapeutics Announces Conclusion of Enrollment for Phase 3 ADVANCE OUTCOMES Study of Ralinepag for Pulmonary Arterial Hypertension

Reuters
·
23 Jun

Paul A. Mahon, EVP & General Counsel, Reports Disposal of Common Shares in United Therapeutics Corporation

Reuters
·
16 Jun

United Therapeutics Is Maintained at Neutral by B of A Securities

Dow Jones
·
12 Jun

Wells Fargo Sticks to Their Hold Rating for United Therapeutics (UTHR)

TIPRANKS
·
11 Jun

CFO and Treasurer James Edgemond Reports Disposal of Common Shares of United Therapeutics Corporation

Reuters
·
11 Jun

United Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since August 2011 -- Data Talk

Dow Jones
·
10 Jun

Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints

MT Newswires Live
·
10 Jun

United Therapeutics falls after Insmed’s TPIP meets endpoints in study

TIPRANKS
·
10 Jun

CFO and Treasurer James Edgemond Reports Disposal of Common Shares in United Therapeutics Corporation

Reuters
·
04 Jun